Advertisement

Bulletin of Experimental Biology and Medicine

, Volume 156, Issue 5, pp 631–634 | Cite as

Pluronics Suppress Association of Low-Density Lipoproteins Inducing Atherogenesis

  • A. A. Mel’nichenkoEmail author
  • D. V. Aksenov
  • O. M. Panasenko
  • A. A. Yaroslavov
  • I. A. Sobenin
  • A. N. Orehov
Article

We studied the effect of pluronics P85, L61, and F68 with different hydrophilic-lipophilic characteristics on association of LDL. It was found that pluronics with pronounced hydrophobic properties (P85 and L61) in concentrations close to or surpassing the critical concentration of micelle formation inhibited LDL association, while hydrophilic pluronic F68 in all concentrations had no effect on LDL association.

Key Words

lipoproteins lipoprotein association pluronics atherosclerosis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    P. Alaupovic, Atherosclerosis, 13, No. 2, 141-146 (1971).PubMedCrossRefGoogle Scholar
  2. 2.
    S. R. Bates and R. W. Wissler, Biochim. Biophys. Acta, 450, No. 1, 78-88 (1976).PubMedCrossRefGoogle Scholar
  3. 3.
    E. V. Batrakova, S. Li, V. Y. Alakhov, et al., Pharmacol. Exp. Ther., 304, No. 2, 845-854 (2003).CrossRefGoogle Scholar
  4. 4.
    A. M. Fogelman, I. Shechter, J. Seager, et al., Proc. Natl. Acad. Sci. USA, 77, No. 4, 2214-2218 (1980).PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    J. L. Goldstein, Y. K. Ho, S. K. Basu, and M. S. Brown, Proc. Natl. Acad. Sci. USA, 76, No. 1, 333-337 (1979).PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    J. C. Khoo, E. Miller, P. McLoughlin, and В. Steinberg, J. Lipid Res., 31, No. 4, 645 (1990).PubMedGoogle Scholar
  7. 7.
    M. F. Lopes-Virella, R. L. Klein, T. J. Lyons, et al., Diabetes, 37, No. 5, 550-557 (1988).PubMedCrossRefGoogle Scholar
  8. 8.
    R. W. Mahley, T. L. Innerarity, K. H. Weisgraber, and S. Y. Oh, J. Clin. Invest., 64, No. 3, 743-750 (1979).PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    R. Ross and L. Harker, Science, 193, 1094-1100 (1976).PubMedCrossRefGoogle Scholar
  10. 10.
    R. M. Talbot, J. D. del Rio, and P. D. Weinberg, J. Lipid Res., 44, No. 4, 837-845 (2003).PubMedCrossRefGoogle Scholar
  11. 11.
    V. V. Tertov, V. V. Kaplun, and A. A. Orekhov, Atherosclerosis, 138, No. 2, 183-195 (1998).PubMedCrossRefGoogle Scholar
  12. 12.
    V. V. Tertov, I. A. Sobenin, Z. A. Gabbasov, et al., Biochem. Biophys. Res. Commun., 16, No. 1, 489-494 (1989).CrossRefGoogle Scholar
  13. 13.
    V. V. Tertov, I. A. Sobenin, Z. A. Gabbasov, et al., Lab. Invest., 67, No. 5, 665-675 (1992).PubMedGoogle Scholar
  14. 14.
    S. V. Vinogradov, E. V. Batrakova, S. Li, and A. V. Kabanov, J. Drug Target., 12, No. 8, 517-526 (2004).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • A. A. Mel’nichenko
    • 1
    Email author
  • D. V. Aksenov
    • 1
  • O. M. Panasenko
    • 2
  • A. A. Yaroslavov
    • 2
  • I. A. Sobenin
    • 1
    • 2
  • A. N. Orehov
    • 1
    • 2
  1. 1.Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical SciencesMoscowRussia
  2. 2.Research Institute of Atherosclerosis (Skolkovo)MoscowRussia

Personalised recommendations